EHRA 2023: Late-Breaking Science Video Collection

Published: 18 April 2023

  • Views:

    Views Icon 2159
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating


For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research and clinical practice. 

About the episode

EHRA 2023 — Join us as we dive into the latest research with investigator, Dr Vivek Reddy (Mount Sinai Hospital, New York, NY, US). He discusses the findings from the MANIFEST-PF registry, adding insights to the evolving landscape of pulsed-field ablation. 

The trial studied the use of the Pentaspline PFA Catheter in patients with paroxysmal or persistent atrial fibrillation in order to understand how the device is being used in clinical practice and its outcomes. 24 centers were involved in the trial, with 1500 patients participating. 


  1. What is the current evidence on the use of the pentaspline PFA catheter?
  2. Please describe the study design of MANIFEST-PF.
  3. Please provide an overview of the cohort enrolled in MANIFEST-PF.
  4. What are the key findings from MANIFEST-PF?
  5. What are some of the unknowns around PFA? What are the promises of this technology? 
  6. What are the planned next steps or future directions based on the findings from MANIFEST-PF?

Recorded on-site at EHRA 2023, Barcelona. 

Faculty Biographies

Vivek Reddy

Vivek Reddy

Director of Cardiac Arrhythmia Services

Dr Vivek Y. Reddy is Director of Cardiac Arrhythmia Services for The Mount Sinai Hospital and Director of Electrophysiology for the Mount Sinai Health System, and The Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology at the Icahn School of Medicine at Mount Sinai.

Dr Reddy is one of the US's premier cardiac electrophysiologists. He leads a team of physician-scientists who are developing and testing advanced therapies for cardiac arrhythmias and heart failure, including catheter ablation for atrial fibrillation and ventricular tachycardia, and device therapies for stroke prevention. Under his leadership, Mount Sinai is the lead investigational site for many multinational clinical trials exploring new arrhythmia procedures and technologies, most recently pulsed field ablation to treat atrial fibrillation. Moreover, in 2014, he implanted the world’s first miniature leadless pacemaker, as well as the first leadless pacemaker in…

View full profile


You must be to comment. If you are not registered, you can register here.